Nivalis Therapeutics Inc (NVLS) was Initiated by Raymond James to “Outperform” and the brokerage firm has set the Price Target at $20. Raymond James advised their investors in a research report released on Sep 13, 2016.
Nivalis Therapeutics Inc opened for trading at $7.69 and hit $7.9 on the upside on Monday, eventually ending the session at $7.77, with a gain of 1.04% or 0.08 points. The heightened volatility saw the trading volume jump to 51,288 shares. Company has a market cap of $120 M.
In a different news, on Jul 6, 2016, David Malcom Rodman (Exec Vice President and CMO) sold 5,950 shares at $4.66 per share price. According to the SEC, on Jun 17, 2016, Jon Congleton (CEO) purchased 5,000 shares at $3.87 per share price. On Dec 11, 2015, Robert E Conway (director) purchased 10,000 shares at $8.10 per share price, according to the Form-4 filing with the securities and exchange commission.
Nivalis Therapeutics Inc. is a United States-based clinical-stage pharmaceutical company. It is engaged in the discovery development and commercialization of product candidates for patients with cystic fibrosis. The Company has developed a portfolio of small molecule inhibitors of S-nitrosoglutathione reductase (GSNOR) which is used to increase and prolong cystic fibrosis transmembrane conductance regulator (CFTR) activity and to decrease inflammation. Its drug candidate portfolio consists of various compounds for oral intravenous (IV) or inhaled administration. The Companys lead clinical candidate is N91115 which is an investigational small molecule that addresses a defect in CFTR resulting from mutations in the CFTR gene. N91115 is designed to stabilize CFTR inside the cell and at the cell surface. N91115 is a CFTR stabilizer that modulates CFTR activity.